The Immunohistochemistry (IHC) Market is expected to be valued at USD 3.5 billion in 2024. Immunohistochemistry (IHC) is projected to grow at a moderate CAGR of 7.8% from 2024 to 2034. The global immunohistochemistry (IHC) market size is predicted to reach USD 7.4 billion by 2034.
| Attributes | Key Insights |
|---|---|
| Estimated Market Size in 2024 | USD 3.5 billion |
| Projected Market Value in 2034 | USD 7.4 billion |
| Value-based CAGR from 2024 to 2034 | 7.8% |
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The immunohistochemistry (IHC) market is expected to expand at a CAGR of 9.9% from 2019 to 2023. Significant automation and machine learning will be deployed in immunohistochemistry throughout the forecast period, along with the release of technologically advanced IHC solutions.
The demand for immunohistochemistry in disease diagnosis has expanded dramatically as IHC technologies have improved. Immunohistochemistry will continue to see strong growth in the market due to the alarming rate at which infectious diseases spread.
Non-small-cell lung cancer patients are expected to benefit from personalized medicine due to its exceptional efficacy. The use of immunohistochemistry will continue to increase through 2034, based on this approach to selecting a course of treatment. A 7.8% CAGR is expected for themarket between 2024 and 2034.
| Historical CAGR from 2019 to 2023 | 9.9% |
|---|---|
| Forecast CAGR from 2024 to 2034 | 7.8% |
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
According to the table provided, South Korea, Japan, and the United Kingdom generate the most revenue in the market. A multiplexing technique is being developed to detect multiple proteins simultaneously in a single tissue sample. Researchers can investigate complex biological relationships and pathways within a single tissue sample through this technique.
Imaging mass cytometry combines mass spectrometry and microscopy to enable highly multiplexed imaging of tissues at the single-cell level. This method gives both spatial information and comprehensive molecular characterization.
Digital pathology, combined with AI algorithms, can potentially transform IHC analysis. Automated picture recognition and quantification can increase accuracy, decrease variability, and enable high-throughput analysis.
| Countries | Forecast CAGRs from 2024 to 2034 |
|---|---|
| The United States | 8% |
| China | 8.5% |
| Japan | 9.2% |
| South Korea | 9.3% |
| The United Kingdom | 9.1% |
Immunohistochemistry (IHC) is expected to be in high demand in the United States. A CAGR of 8% is forecast for the market during the period. Precision medicine projects are increasingly being undertaken in the United States, aiming to customize medical care based on patient's unique molecular profiles.
The field of immunohistochemistry is expanding in the United States due to its importance in finding molecular targets and biomarkers and helping choose treatments. Robust partnerships among academic research institutions, biotechnology businesses, and healthcare providers benefit the United States.
Cooperation between institutions in the United States has catapulted advances in biomarker identification, assay development, and clinical validation in immunohistochemistry. Research outcomes are converted into diagnostic instruments and treatments that are medicinally beneficial.
The immunohistochemistry (IHC) market is predicted to grow in China. A growth rate of 8.5% is anticipated between 2024 and 2034. The country's aging population, changing lifestyles, and environmental conditions are all contributing to a notable increase in cancer deaths. In China, immunohistochemistry is becoming a vital tool for cancer diagnosis and treatment planning, resulting in better patient outcomes.
The government of China has heavily invested in medical facilities and programs to increase access to medical care, including cancer detection and treatment. Immunohistochemistry is expanding in China to improve the diagnosis and treatment of cancer and other diseases.
With the advancement of technology, Japan is expected to dominate the market. A 9.2% CAGR is forecast for the market during the forecast period. Japan is expanding its use of immunohistochemistry for diagnosing and characterizing malignancies because it provides data for individualized treatment plans tailored to the needs of geriatric patients.
Japan is renowned for its contributions to digital pathology and molecular imaging, among other biomedical imaging technologies. In Japan, immunohistochemistry is becoming more popular as part of a larger movement to combine histopathological analysis and modern imaging modalities to enable more accurate and thorough disease characterization and diagnosis.
South Korea has increased healthcare spending to improve access to advanced medical technologies and treatments. By 2034, the market is expected to grow at a CAGR of 9.3%. Immunohistochemistry is increasing in South Korea as healthcare providers invest in state-of-the-art diagnostic capabilities, including immunohistochemical staining techniques, to enhance cancer diagnosis, treatment planning, and patient care. Like many affluent nations, South Korea is going through demographic shifts brought on by an aging population and a rising cancer incidence rate.
A CAGR of 9.1% is projected for the United Kingdom between 2024 and 2034. The United Kingdom has a strong biomedical research community focused on understanding disease mechanisms and developing new diagnostic and therapeutic approaches.
Immunohistochemistry is growing in the United Kingdom as it is widely used in research settings to study protein expression patterns, cellular interactions, and disease pathways, leading to discoveries that advance healthcare and inform clinical practice.
As part of its healthcare policy, the United Kingdom lays a lot of emphasis on early disease identification and prevention. Because it is essential for early cancer identification, screening programs, and risk assessment, immunohistochemistry is becoming increasingly popular in the United Kingdom. This enables prompt interventions and better patient outcomes through focused therapies and surveillance.
An overview of the market's leading segments is provided in this section. Based on the product, the antibodies segment is expected to increase at a CAGR of 7.6% by 2034. Based on the application, the diagnostics segment is expected to expand at a CAGR of 7.5% by 2034.
| Category | CAGR from 2024 to 2034 |
|---|---|
| Antibodies | 7.6% |
| Diagnostics | 7.5% |
Scientists and researchers working on diverse projects in cancer, neuroscience, immunology, and other fields often use IHC to assess protein expression levels. Institutions in academia and science have a high demand for antibodies.
The use of IHC in diagnostic settings is common, especially in pathology labs. The use of antibodies in medical diagnostics may continue to increase. By 2034, the antibodies sector is expected to experience a CAGR of 7.6%.
Antibodies greatly enhance research on diseases at the molecular and cellular levels. The demand for antibodies specific to specific biomarkers increases as new diseases are discovered or current ones become better understood.
IHC is routinely used to diagnose and classify cancers. To subtype tumors and choose an appropriate treatment regimen, pathologists use it to identify specific proteins or antigens associated with several types of cancer. It is predicted that diagnostics will expand at a CAGR of 7.5% between 2024 and 2034.
IHC is critical for discovering prognostic and predictive biomarkers that inform oncology therapy decisions. Detecting markers such as hormone receptors, HER2/neu, and PD-L1 aids in predicting disease progression and response to specific therapy.
IHC can be used to detect infectious agents, which helps to diagnose infectious disorders. Antigens and viral proteins can be visualized in tissue samples, enabling the detection of pathogens.
Immunohistochemistry (IHC) companies seek collaborations and strategic partnerships to expand their capabilities. Healthcare partnerships are more important than ever. Innovative medical treatments are increasingly being brought to patients worldwide through collaboration between industry specialists.
Key Market Developments
| Attributes | Details |
|---|---|
| Estimated Market Size in 2024 | USD 3.5 billion |
| Projected Market Valuation in 2034 | USD 7.4 billion |
| Value-based CAGR 2024 to 2034 | 7.8% |
| Forecast Period | 2024 to 2034 |
| Historical Data Available for | 2019 to 2023 |
| Market Analysis | Value in USD billion |
| Key Regions Covered | North America; Latin America; Western Europe; Eastern Europe; South Asia and Pacific; East Asia; The Middle East and Africa |
| Key Market Segments Covered | Product, Application, End User, Region |
| Key Countries Profiled | The United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, Poland, Russia, Czech Republic, Romania, India, Bangladesh, Australia, New Zealand, China, Japan, South Korea, GCC countries, South Africa, Israel |
| Key Companies Profiled | Thermo Fisher Scientific Inc.; F. Hoffmann-La Roche Ltd.; Merck KGaA; Danaher Corporation; Perkinelmer Inc.; Bio-Rad Laboratories Inc.; Cell Signaling Technology Inc.; Bio SB; Agilent Technologies Inc.; Abcam plc. |
As of 2024, the immunohistochemistry (IHC) market is expected to reach USD 3.5 billion.
The market value of immunohistochemistry (IHC) is expected to reach USD 7.4 billion by 2034.
A growth rate of 7.8% is expected for immunohistochemistry (IHC) between 2024 and 2034.
The antibody market is expected to expand at a CAGR of 7.6% between 2034 and 2041.
With a CAGR of 9.3%, South Korea is expected to dominate the market.
| Market Size (2024) | USD 266.83 billion |
|---|---|
| Market Value (2034) | USD 581.42 billion |
| Market CAGR (2024 to 2034) | 8.1% |
| Projected Forecast Value (2023) | USD 113.54 billion |
|---|---|
| Projected Forecast Value (2033) | USD 206.96 billion |
| Growth rate (2023 to 2033) | 6.2% CAGR |
| Market Value (2021) | USD 2.08 Billion |
|---|---|
| Market Value (2032) | USD 4.5 Billion |
| Market CAGR (2022 to 2032) | 7.25% |
| Market Value (2021) | USD 14.2 Billion |
|---|---|
| Market Value (2032) | USD 72.69 Billion |
| CAGR (2022 to 2032) | 16% |
Explore In-vitro Diagnostics Devices Insights
View Reports
Immunohistochemistry (IHC) Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
